These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Long-term survival and toxicity in patients with neuroendocrine tumors treated with Kennedy KR; Turner JH; MacDonald WBG; Claringbold PG; Boardman G; Ransom DT Cancer; 2022 Jun; 128(11):2182-2192. PubMed ID: 35363879 [TBL] [Abstract][Full Text] [Related]
23. The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with Alipour R; Jackson P; Bressel M; Hogg A; Callahan J; Hicks RJ; Kong G Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):2997-3010. PubMed ID: 37184682 [TBL] [Abstract][Full Text] [Related]
24. Long-Term Efficacy, Survival, and Safety of [ Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192 [No Abstract] [Full Text] [Related]
25. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Severi S; Nanni O; Bodei L; Sansovini M; Ianniello A; Nicoletti S; Scarpi E; Matteucci F; Gilardi L; Paganelli G Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):881-8. PubMed ID: 23443937 [TBL] [Abstract][Full Text] [Related]
27. Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours. Almeamar H; Cullen L; Murphy DJ; Crowley RK; Toumpanakis C; Welin S; O'Shea D; O'Toole D J Neuroendocrinol; 2022 Jun; 34(6):e13138. PubMed ID: 35485450 [TBL] [Abstract][Full Text] [Related]
28. Predicting the survival probability of functional neuroendocrine tumors treated with peptide receptor radionuclide therapy: Serbian experience. Vukomanovic V; Nedic KV; Radojevic MZ; Dagovic A; Milosavljevic N; Markovic M; Ignjatovic V; Simic Vukomanovic I; Djukic S; Sreckovic M; Backovic M; Vuleta M; Djukic A; Vukicevic V; Ignjatovic V Front Endocrinol (Lausanne); 2023; 14():1270421. PubMed ID: 38317712 [TBL] [Abstract][Full Text] [Related]
29. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Paganelli G; Sansovini M; Ambrosetti A; Severi S; Monti M; Scarpi E; Donati C; Ianniello A; Matteucci F; Amadori D Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1845-51. PubMed ID: 24615468 [TBL] [Abstract][Full Text] [Related]
30. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971 [TBL] [Abstract][Full Text] [Related]
31. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296 [TBL] [Abstract][Full Text] [Related]
32. Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience. Kesavan M; Turner JH Cancer Biother Radiopharm; 2016 Aug; 31(6):189-98. PubMed ID: 27419665 [TBL] [Abstract][Full Text] [Related]
33. Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of Shah RG; Merlin MA; Adant S; Zine-Eddine F; Beauregard JM; Shah GM Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435224 [TBL] [Abstract][Full Text] [Related]
34. Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with Minczeles NS; de Herder WW; Feelders RA; Verburg FA; Hofland J; Brabander T J Nucl Med; 2023 Jan; 64(1):40-46. PubMed ID: 35680417 [TBL] [Abstract][Full Text] [Related]
35. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Sabet A; Dautzenberg K; Haslerud T; Aouf A; Sabet A; Simon B; Mayer K; Biersack HJ; Ezziddin S Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1238-46. PubMed ID: 25808630 [TBL] [Abstract][Full Text] [Related]
36. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment. Hamiditabar M; Ali M; Roys J; Wolin EM; OʼDorisio TM; Ranganathan D; Tworowska I; Strosberg JR; Delpassand ES Clin Nucl Med; 2017 Jun; 42(6):436-443. PubMed ID: 28263217 [TBL] [Abstract][Full Text] [Related]
37. High clinical and morphologic response using Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267 [TBL] [Abstract][Full Text] [Related]